Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Pili

Showing results (51-60 of 223) with videos related to

Pageof 23
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 15, 2025
Receiving immunotherapy for the treatment of advanced renal cell carcinoma is associated with higher burden of illness, coagulopathy, cardiac arrhythmia, and disparitiesSusan Eichhorn, Roberto Pili, Joel B Epstein, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2007
Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugsHenk M W Verheul, David Z Qian, Michael A Carducci, et al.
Investigational New Drugs|October 27, 2019
Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinomaAnthony Wood, Saby George, Nabil Adra, et al.
Plos One|July 30, 2014
Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancerShengYu Ku, Elena Lasorsa, Remi Adelaiye, et al.
Journal of Dermatological Science|May 29, 2014
Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cellsYukihiko Kato, Ikuyo Yoshino, Chizu Egusa, et al.
Journal of Visualized Experiments : Jove|May 20, 2014
Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomyAmanda Tracz, Michalis Mastri, Christina R Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patientsJing Li, Michael B Jameson, Bruce C Baguley, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
CLO26-103: Global and National Impact of Behavioral Risk Factors on Tracheal, Bronchial, and Lung Cancer PatientsAshu Singh, Baban Kumar, Chloe Wen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 29, 2026
CLO26-103: Global and National Impact of Behavioral Risk Factors on Tracheal, Bronchial, and Lung Cancer PatientsAshu Singh, Baban Kumar, Chloe Wen, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 15, 2006
A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasmaMing Zhao, Michelle A Rudek, Aleksandr Mnasakanyan, et al.
Pageof 23

Showing results (51-60 of 223) with videos related to

Sort By:
Pageof 23
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 15, 2025
Receiving immunotherapy for the treatment of advanced renal cell carcinoma is associated with higher burden of illness, coagulopathy, cardiac arrhythmia, and disparitiesSusan Eichhorn, Roberto Pili, Joel B Epstein, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2007
Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugsHenk M W Verheul, David Z Qian, Michael A Carducci, et al.
Investigational New Drugs|October 27, 2019
Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinomaAnthony Wood, Saby George, Nabil Adra, et al.
Plos One|July 30, 2014
Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancerShengYu Ku, Elena Lasorsa, Remi Adelaiye, et al.
Journal of Dermatological Science|May 29, 2014
Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cellsYukihiko Kato, Ikuyo Yoshino, Chizu Egusa, et al.
Journal of Visualized Experiments : Jove|May 20, 2014
Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomyAmanda Tracz, Michalis Mastri, Christina R Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patientsJing Li, Michael B Jameson, Bruce C Baguley, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
CLO26-103: Global and National Impact of Behavioral Risk Factors on Tracheal, Bronchial, and Lung Cancer PatientsAshu Singh, Baban Kumar, Chloe Wen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 29, 2026
CLO26-103: Global and National Impact of Behavioral Risk Factors on Tracheal, Bronchial, and Lung Cancer PatientsAshu Singh, Baban Kumar, Chloe Wen, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 15, 2006
A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasmaMing Zhao, Michelle A Rudek, Aleksandr Mnasakanyan, et al.
Pageof 23